CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution designed to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company aims to address critical unmet medical needs in the healthcare sector, particularly for patients undergoing dialysis who are at high risk of infections. CorMedix's efforts are centered on bringing DefenCath to market and potentially expanding its applications to other patient populations.

CorMedix Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CRMD. The company's stock is traded in US Dollars (USD), reflecting its primary operations and headquarters in the United States. As a Nasdaq-listed company, CorMedix is subject to the regulatory and reporting requirements of the US Securities and Exchange Commission (SEC), providing transparency for investors.

CorMedix Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for serious medical conditions. Its primary area of focus is on antimicrobial solutions to prevent infections in patients with kidney failure, which falls under the broader biopharmaceutical field. The company's work involves rigorous clinical trials and regulatory approvals to bring its products to market.

CorMedix Inc. is headquartered in Parsippany, New Jersey, United States. The company primarily serves the US market, focusing on developing and commercializing its therapeutic products for life-threatening diseases and conditions within the country. Its lead product candidate, DefenCath, targets adult patients with kidney failure who are at risk of catheter-related bloodstream infections, a significant healthcare concern in the US. The company's operations are centered in the US, and it aims to address unmet medical needs in the American healthcare system.

CorMedix Inc. operates as a biopharmaceutical company with a business model centered on developing and commercializing therapeutic products for life-threatening diseases. Its primary focus is on DefenCath, an antimicrobial catheter lock solution intended to reduce catheter-related bloodstream infections in adult kidney failure patients. The company generates revenue through the sale of its approved products, and it invests heavily in research and development to advance its pipeline. CorMedix also seeks partnerships and collaborations to support the development and distribution of its therapies. As a development-stage company, it has not yet generated significant product revenue, but it aims to commercialize DefenCath following regulatory approval.